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Recently, Schmidt and colleagues re-
ported that immunoglobulin Kappa C 
(IGKC) predicts a favourable response to 
chemotherapy and better metastasis-free 
survival in breast cancer patients (Schmidt 
et al., 2012). The authors validated the 
prognostic and predictive role of IGKC in 
1,810 breast cancer, 1,056 non-small cell 
lung cancer and 513 colorectal cancer pa-
tient samples. The identification of IGKC 
as a single and robust marker of the im-
mune response represents a major progress 
in the field of clinical tumour immunology 
and biomarkers. During the past decades, 
the search for prognostic and predictive 
markers of human tumours represented a 
major research focus (Perou et al., 2000; 
Desmedt et al., 2007; Cadenas et al., 2010; 
Hellwig et al., 2010; Kammers et al., 2011; 
Hardelauf et al., 2011; Lee et al., 2010; 
Mariani et al., 2010). The prognostic rele-
vance of proliferation-associated genes 
(Schmidt et al., 2009a, b, 2011) and – in 
breast cancer – gene signatures associated 
with steroid hormone receptors and ERBB2 
has been consistently demonstrated (Des-
medt et al., 2007; Brase et al., 2010; Petry 
et al., 2010). In contrast, the role of the im-
mune system remained controversial. On 
the one hand, experimental and animal 
studies suggest that the humoral immune 
system may stimulate tumour growth, pos-
sibly by cytokine secretion (Tan and 
Coussens, 2008; Inoue et al., 2006; review: 
Schmidt et al., 2009a). However, several 
reports speculated that antibodies secreted 
after B-cell expansion may also control tu-
mour growth by aiding destruction of tu-
mour cells (review: Schmidt et al., 2010; 
2011). Only as recently as 2008, was it fi-
nally made clear that a B-cell/plasma cell 
metagene, indicating infiltration of tumours 
with plasma cells, is associated with better 
prognosis in breast cancer (Schmidt et al., 
2008). This effect is stronger in fast prolif-
erating carcinomas. In this study, a meta-
gene consisting of 60 individual genes was 
used to evaluate plasma cell infiltration. In 
the clinic however, routine determination of 
a 60-gene signature would be too laborious. 
Therefore, the major breakthrough of the 
large validation study is that the 60-gene B-
cell/plasma cell metagene can be replaced 
by a single robust marker without loss of 
prognostic/predictive power: IGKC 
(Schmidt et al., 2012). The key messages of 
the study are: 
 
 IGKC is associated with good progno-
sis in breast, lung and colon cancers 
 IGKC indicates tumour-infiltrating 
plasma cells 
 Besides its prognostic relevance in pa-
tients who did not receive systemic 
chemotherapy, IGKC also predicts fa-
vourable responses to anthracycline-
based chemotherapy in breast cancer 
 IGKC can be detected immunohisto-
chemically in paraffin slides using 
commercially available antibodies. Al-
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ternatively, it can be measured by qRT-
PCR using RNA isolated from fresh 
frozen tumour tissue or from paraffin 
material. Immunostaining results and 
RNA expression levels correlate, and 
the high expression of IGKC obtained 
using both techniques is similarly asso-
ciated with better prognosis. 
 
Currently, there are no alternative 
markers available for the humoral immune 
system; therefore, IGKC is likely to play a 
central role as a prognostic and predictive 
factor of solid carcinomas.  
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